Literature DB >> 24232002

Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

Justin J Kang1, Liming Shu, James L Park, James A Shayman, Peter F Bodary.   

Abstract

A defect in the gene for the lysosomal enzyme α-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. However, gastrointestinal symptoms are often first observed during childhood in these patients and are not well understood. In this study, we demonstrate an age-dependent microvasculopathy of the mesenteric artery (MA) in a murine model of Fabry disease (Gla-knockout mice) resulting from dysregulation of the vascular homeostatic enzyme endothelial nitric oxide synthase (eNOS). The progressive accumulation of Gb3 in the MA was confirmed by thin-layer chromatographic analysis. A total absence of endothelium-dependent dilation was observed in MAs from mice at 8 mo of age, while suppression of ACh-mediated vasodilation was evident from 2 mo of age. Endothelium-independent dilation with sodium nitroprusside was normal compared with age-matched wild-type mice. The microvascular defect in MAs from Fabry mice was endothelium-dependent and associated with suppression of the active homodimer of eNOS. Phosphorylation of eNOS at the major activation site (Ser(1179)) was significantly downregulated, while phosphorylation at the major inhibitory site (Thr(495)) was remarkably enhanced in MAs from aged Fabry mice. These profound alterations in eNOS bioavailability at 8 mo of age were observed in parallel with high levels of 3-nitrotyrosine, suggesting increased reactive oxygen species along with eNOS uncoupling in this vascular bed. Overall, the mesenteric microvessels in the setting of Fabry disease were observed to have an early and profound endothelial dysfunction associated with elevated reactive nitrogen species and decreased nitric oxide bioavailability.

Entities:  

Keywords:  Fabry disease; glycosphingolipids; myograph; reactive nitrogen species; renal failure

Mesh:

Substances:

Year:  2013        PMID: 24232002      PMCID: PMC3920075          DOI: 10.1152/ajpgi.00185.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  27 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite.

Authors:  Ming-Hui Zou; Chaomei Shi; Richard A Cohen
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

4.  Ca2+-activated K+ channels of small and intermediate conductance control eNOS activation through NAD(P)H oxidase.

Authors:  Pablo S Gaete; Mauricio A Lillo; Nicolás M Ardiles; Francisco R Pérez; Xavier F Figueroa
Journal:  Free Radic Biol Med       Date:  2011-12-23       Impact factor: 7.376

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase.

Authors:  B J Michell; T Tiganis; D Stapleton; F Katsis; D A Power; A T Sim; B E Kemp
Journal:  J Biol Chem       Date:  2001-04-05       Impact factor: 5.157

7.  Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity.

Authors:  I Fleming; B Fisslthaler; S Dimmeler; B E Kemp; R Busse
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

8.  An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice.

Authors:  R P Brandes; F H Schmitz-Winnenthal; M Félétou; A Gödecke; P L Huang; P M Vanhoutte; I Fleming; R Busse
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

9.  Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis.

Authors:  Daniel T Eitzman; Peter F Bodary; Yuechun Shen; Christian G Khairallah; Susan R Wild; Akira Abe; Jacqueline Shaffer-Hartman; James A Shayman
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

10.  Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production.

Authors:  Michelle I Lin; David Fulton; Roger Babbitt; Ingrid Fleming; Rudi Busse; Kirkwood A Pritchard; William C Sessa
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  9 in total

1.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

2.  Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.

Authors:  Xing-Li Meng; Taniqua S Day; Nathan McNeill; Paula Ashcraft; Thomas Frischmuth; Seng H Cheng; Zhi-Ping Liu; Jin-Song Shen; Raphael Schiffmann
Journal:  J Inherit Metab Dis       Date:  2016-03-10       Impact factor: 4.982

3.  Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.

Authors:  Siamak Jabbarzadeh-Tabrizi; Michel Boutin; Taniqua S Day; Mouna Taroua; Raphael Schiffmann; Christiane Auray-Blais; Jin-Song Shen
Journal:  J Lipid Res       Date:  2020-08-31       Impact factor: 5.922

Review 4.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

5.  Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.

Authors:  Sun Hee Heo; Eungu Kang; Yoon-Myung Kim; Heounjeong Go; Kyung Yong Kim; Jae Yong Jung; Minji Kang; Gu-Hwan Kim; Jae-Min Kim; In-Hee Choi; Jin-Ho Choi; Sung-Chul Jung; Robert J Desnick; Han-Wook Yoo; Beom Hee Lee
Journal:  J Med Genet       Date:  2017-08-23       Impact factor: 6.318

6.  Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy.

Authors:  Jefferson Loso; Natalie Lund; Maxim Avanesov; Nicole Muschol; Susanne Lezius; Kathrin Cordts; Edzard Schwedhelm; Monica Patten
Journal:  Front Cardiovasc Med       Date:  2018-08-15

7.  Voluntary wheel running activates Akt/AMPK/eNOS signaling cascades without improving profound endothelial dysfunction in mice deficient in α-galactosidase A.

Authors:  Justin J Kang; Taylour A Treadwell; Peter F Bodary; James A Shayman
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

8.  Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.

Authors:  PauloC Gregório; Regiane S da Cunha; Gilson Biagini; Bruna Bosquetti; Júlia Budag; Alberto Ortiz; Maria Dolores Sánchez-Niño; Fellype C Barreto; Andréa E M Stinghen
Journal:  Toxicol Appl Pharmacol       Date:  2021-01-21       Impact factor: 4.219

9.  Dysregulated DNA methylation in the pathogenesis of Fabry disease.

Authors:  Jin-Song Shen; Uthra Balaji; Kunitoshi Shigeyasu; Yoshinaga Okugawa; Siamak Jabbarzadeh-Tabrizi; Taniqua S Day; Erland Arning; John Marshall; Seng H Cheng; Jinghua Gu; Raphael Schiffmann; Teodoro Bottiglieri; Ajay Goel
Journal:  Mol Genet Metab Rep       Date:  2022-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.